SAFC Pharma vice president David Feldker spoke with in-pharmatechnologist about the firm’s reasons for investing $12m (€9.7m) at facilities in St Louis, Missouri site and Irvine, Scotland.
Foremost among these, according to Feldker, is the push towards disposable processing technology in the biomanufacturing industry is driving demand for liquid media and the preparation of specialist reagents.
Feldker went on to explain that the investment also fits with the recently announced expansion of its dry powder media manufacturing facility in Lenexa, Kansas and wider expansion of SAFC’s range of cell culture technologies.
And for the medium term Feldker expects the biodrug sector to continue to drive demand. He suggested that the growth of the gene therapy market and personalised medicine sector, coupled with the need to reduce production costs and boost efficiency would remain.